When Andrew Huberman mentions a peptide on his podcast, sales spike globally. Peter Attia's Drive discussions push the same effect. Ben Greenfield's blog posts and podcast episodes have driven interest in compounds most researchers hadn't heard of. This guide is the honest cross-reference: what have these advocates actually said, with sources, doses, and the caveats each has explicitly issued. We avoid inference — every claim below is either a direct quote, a linked source, or clearly flagged as our own analysis.
Why 'Named Advocate' Isn't Evidence — And What It Actually Is
Named-advocate protocols are useful for setting a starting dose and a discussion frame, but they are not a substitute for evidence tiers.
A named advocate saying 'I use 500 mcg BPC-157 daily' is not evidence that BPC-157 works. It's evidence that a specific person, at a specific time, chose that dose. Useful for calibrating a starting point, not for validating efficacy.
What named advocates are useful for:
- Setting a defensible starting dose (people generally start where informed users start)
- Understanding the framing — what target biomarkers or outcomes they're tracking
- Cross-checking safety flags (if a serious advocate warns off a compound, take that seriously)
What they are not useful for:
- Deciding whether a compound 'works' — that's what evidence tiers are for
- Determining optimal dose for you specifically
- Substituting for baseline bloodwork
Andrew Huberman — Sermorelin, Ipamorelin, BPC-157
Huberman's public discussions have focused on growth-hormone secretagogues and BPC-157, with clear repeated safety framing.
Huberman has discussed peptides across several Huberman Lab episodes. His pattern is consistent: he identifies mechanism, cites the primary literature, and explicitly acknowledges the human evidence gaps. This is a healthier framing than most peptide content online.
Growth Hormone Secretagogues: Huberman has discussed sermorelin, ipamorelin, and tesamorelin across multiple episodes. His framing emphasises the pulsatile physiology of endogenous GH release and the theoretical safety advantage of secretagogues over exogenous GH.
Reported doses discussed: Sermorelin 200-500 mcg subq before bed; ipamorelin 100-300 mcg 2-3x/day; tesamorelin per label (2 mg subq daily).
BPC-157: Huberman has discussed BPC-157 as one of the most-studied repair peptides preclinically, with explicit acknowledgment that human data is limited. He has emphasised the Zagreb research group's tendon and gut work.
The pattern to notice: Huberman consistently pairs peptide discussion with foundational-behaviour framing — sleep, protein intake, resistance training. He does not frame peptides as substitutes for baseline behaviours.
Peter Attia — Semaglutide, Rapamycin (context), and Longevity Framing
Attia's peptide discussion sits inside a broader longevity/medicine framework — most importantly around GLP-1 agonists and metabolic health.
Peter Attia has been more measured on peptides than Huberman, focusing primarily on semaglutide and related GLP-1 agonists in the context of metabolic health and longevity. His Drive episodes on GLP-1s are widely cited.
Attia's core framing: GLP-1 agonists are properly studied medications for a real condition (obesity-driven metabolic disease). Their appropriate use is clinical, not aesthetic. Attia has repeatedly cautioned against microdosing GLP-1s for weight loss in people who don't clinically need them.
On other peptides, Attia has been comparatively cautious. He has discussed the growth-hormone secretagogue class in general terms but not endorsed specific protocols. His approach is closer to: 'the evidence bar for licensed medicines is very high, and most peptides don't clear it.'
Rapamycin (not strictly a peptide, but often bracketed with the class): Attia has been the most-cited advocate for rapamycin in the longevity space, using it himself and discussing weekly-dose protocols. He is explicit that this is off-label and experimental.
What Attia does not discuss much: the wellness-culture peptides — MOTS-c, epitalon, dihexa, DSIP. That silence is meaningful.
Ben Greenfield — The Comprehensive Peptide Advocate
Greenfield has discussed the broadest range of peptides publicly, including many Tier C/D compounds, with variable evidence framing.
Ben Greenfield has written and spoken about more peptides than perhaps any other named public figure — from BPC-157 and TB-500 through epitalon, SS-31, and various melanocortins. His blog and podcast are among the most-referenced sources in the peptide-user community.
Where Greenfield's coverage is strongest:
- Stacking philosophy — combining mechanisms rather than duplicating them
- Cycling — his default is 4-6 weeks on, comparable time off, particularly for GH secretagogues
- Practical logistics — reconstitution, storage, injection technique
Where the framing weakens:
- Enthusiasm for Tier D compounds without matching evidence caveats
- Personal-anecdote framing where a controlled comparison would be more informative
- Occasional conflation of mechanism with clinical benefit
The Greenfield material is genuinely useful as a starting point for what protocols experienced users have run — but requires calibration against the evidence tier of the compound in question.
Cross-Checking Named-Advocate Protocols Against Evidence Tiers
The named-advocate dose is one data point. The tier tells you how much weight to give it.
A useful mental model: named-advocate protocols are worth more when the compound sits at Tier S or A (because the compound is well-characterised and the advocate is describing a personalised optimisation within a validated framework) and worth less when the compound sits at Tier C or D (because nobody has enough data to know if the dose is anywhere close to optimal).
Practical translation:
- Huberman on sermorelin (Tier B/A) — high signal, credible starting point
- Attia on semaglutide (Tier S) — highest signal, clinical framing
- Greenfield on epitalon (Tier D) — interesting starting point, requires your own bloodwork tracking
Safety Notes Named Advocates Consistently Highlight
The best advocates converge on the same safety flags — cycling, bloodwork monitoring, and starting low.
Across Huberman, Attia, and Greenfield — despite their different tiers of enthusiasm — three safety notes recur:
- Bloodwork before, during, after. None of them advocate flying blind. Baseline labs are non-negotiable, and mid-protocol labs are strongly recommended for anything more than a few weeks.
- Cycle GH secretagogues. All three have discussed the risk of pituitary desensitisation with continuous GH-secretagogue use. Standard framing is 4-8 weeks on, similar time off.
- Start below the target dose. Tolerance and idiosyncratic responses vary. Half-dose for the first week is a defensible universal starting point.
These converge because they're mechanism-driven, not opinion-driven.
Frequently Asked Questions
Andrew Huberman has discussed BPC-157 on the Huberman Lab podcast and referenced the preclinical evidence. He has not, as far as we can find, publicly stated a personal current protocol. His framing has always been that human data is limited and mechanism-based interest does not equal clinical validation.
Peter Attia has consistently framed semaglutide and tirzepatide as appropriate for their licensed indications (type 2 diabetes and clinical obesity). He has cautioned against microdosing for aesthetic weight loss in people who don't clinically need them, and generally supports the label doses of Ozempic/Wegovy (semaglutide 0.25-2.4 mg weekly) when clinically indicated.
No — they are one person's dose choice at one point in time, not controlled evidence. They're useful for setting a starting frame but not for validating that a compound works. Always cross-reference with the compound's evidence tier and, ideally, primary-source citations.
Greenfield's public position is as a broad experimenter and self-quantifier. He has run more personal protocols than most other named advocates and has documented them extensively. The value is in the practical logistics and stacking philosophy; the limitation is that personal anecdote does not scale to population-level evidence.
Peter Attia is consistently the most conservative — he prioritises licensed medications with strong RCT evidence and is publicly sceptical of most wellness-culture peptides. This reflects his background in evidence-based medicine and his focus on longevity outcomes with long-term data.